Krystal Biotech, Inc. (NASDAQ:KRYS) Position Cut by BNP Paribas Financial Markets

BNP Paribas Financial Markets lowered its position in shares of Krystal Biotech, Inc. (NASDAQ:KRYS - Free Report) by 25.3% in the 4th quarter, according to its most recent disclosure with the SEC. The fund owned 7,789 shares of the company's stock after selling 2,644 shares during the period. BNP Paribas Financial Markets' holdings in Krystal Biotech were worth $1,220,000 as of its most recent filing with the SEC.

A number of other large investors have also modified their holdings of KRYS. Norges Bank bought a new position in Krystal Biotech in the 4th quarter worth about $34,391,000. Raymond James Financial Inc. bought a new stake in Krystal Biotech during the 4th quarter valued at $15,989,000. Price T Rowe Associates Inc. MD boosted its position in Krystal Biotech by 16.2% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 509,459 shares of the company's stock worth $79,812,000 after acquiring an additional 71,200 shares during the period. TimesSquare Capital Management LLC lifted its holdings in Krystal Biotech by 39.1% in the fourth quarter. TimesSquare Capital Management LLC now owns 158,868 shares of the company's stock worth $24,888,000 after purchasing an additional 44,646 shares during the period. Finally, Vanguard Group Inc. grew its position in Krystal Biotech by 1.0% in the 4th quarter. Vanguard Group Inc. now owns 2,878,451 shares of the company's stock valued at $450,938,000 after buying an additional 28,707 shares in the last quarter. Institutional investors and hedge funds own 86.29% of the company's stock.

Insider Activity at Krystal Biotech

In other Krystal Biotech news, CAO Kathryn Romano sold 750 shares of the firm's stock in a transaction dated Thursday, February 27th. The stock was sold at an average price of $175.22, for a total transaction of $131,415.00. Following the completion of the sale, the chief accounting officer now directly owns 12,604 shares in the company, valued at approximately $2,208,472.88. This trade represents a 5.62% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, insider Suma Krishnan sold 25,000 shares of the firm's stock in a transaction dated Thursday, March 13th. The stock was sold at an average price of $177.79, for a total value of $4,444,750.00. Following the sale, the insider now owns 1,463,711 shares of the company's stock, valued at $260,233,178.69. The trade was a 1.68% decrease in their ownership of the stock. The disclosure for this sale can be found here. 13.70% of the stock is currently owned by corporate insiders.

Analysts Set New Price Targets

KRYS has been the topic of a number of recent analyst reports. Guggenheim dropped their price target on shares of Krystal Biotech from $195.00 to $189.00 and set a "buy" rating on the stock in a research report on Wednesday, May 7th. Jefferies Financial Group assumed coverage on Krystal Biotech in a research report on Wednesday, March 5th. They set a "buy" rating and a $245.00 price target on the stock. Chardan Capital restated a "buy" rating and issued a $219.00 price objective on shares of Krystal Biotech in a report on Wednesday, May 7th. Citigroup decreased their target price on Krystal Biotech from $215.00 to $155.00 and set a "neutral" rating for the company in a research note on Friday. Finally, Cantor Fitzgerald reaffirmed an "overweight" rating and set a $215.00 target price on shares of Krystal Biotech in a research note on Thursday, February 20th. One research analyst has rated the stock with a hold rating, seven have issued a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of "Buy" and an average target price of $211.13.

Krystal Biotech Stock Up 1.3%

NASDAQ:KRYS opened at $132.29 on Tuesday. Krystal Biotech, Inc. has a 1-year low of $127.40 and a 1-year high of $219.34. The firm has a market capitalization of $3.82 billion, a price-to-earnings ratio of 44.24 and a beta of 0.79. The stock has a fifty day simple moving average of $165.82 and a 200 day simple moving average of $168.23.

Krystal Biotech (NASDAQ:KRYS - Get Free Report) last released its quarterly earnings results on Tuesday, May 6th. The company reported $1.20 earnings per share for the quarter, missing analysts' consensus estimates of $1.38 by ($0.18). Krystal Biotech had a net margin of 30.69% and a return on equity of 11.41%. The company had revenue of $88.18 million during the quarter, compared to analyst estimates of $98.66 million. Equities analysts predict that Krystal Biotech, Inc. will post 6.14 earnings per share for the current year.

Krystal Biotech Profile

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).

Want to see what other hedge funds are holding KRYS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Krystal Biotech, Inc. (NASDAQ:KRYS - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.